» Articles » PMID: 33516237

Infiltrating Immune Cells in Benign Breast Disease and Risk of Subsequent Invasive Breast Cancer

Overview
Specialty Oncology
Date 2021 Jan 31
PMID 33516237
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: It is well established that tumors are antigenic and can induce an immune response by the host, entailing lymphocytic infiltration of the tumor and surrounding stroma. The extent and composition of the immune response to the tumor, assessed through evaluation of tumor-infiltrating lymphocyte counts, has been shown in many studies to have prognostic and predictive value for invasive breast cancer, but currently, there is little evidence regarding the association between infiltrating immune cell counts (IICCs) in women with benign breast disease (BBD) and risk of subsequent invasive breast cancer.

Methods: Using a cohort of 15,395 women biopsied for BBD at Kaiser Permanente Northwest, we conducted a nested case-control study in which cases were women who developed a subsequent invasive breast cancer during follow-up and controls were individually matched to cases on age at BBD diagnosis. We assessed IICCs in normal tissue and in the BBD lesions, and we used unconditional logistic regression to estimate the multivariable odds ratios (OR) and 95% confidence intervals (CI) for the associations between IICCs and breast cancer risk.

Results: There was no association between the IICC in normal tissue (multivariable OR per 5% increase in IICC = 1.05, 95% CI = 0.96-1.16) or in the BBD lesion (OR per 5% increase in IICC = 1.06, 95% CI = 0.96-1.18) and risk of subsequent invasive breast cancer. Also, there were no associations within subgroups defined by menopausal status, BBD histology, BMI, and history of smoking.

Conclusion: The results of this study suggest that IICCs in BBD tissue are not associated with altered risk of subsequent invasive breast cancer.

Citing Articles

Bioinformatics insights into the role of GFPT1 in breast invasive carcinoma: implications for tumor prognosis, immune modulation, and therapeutic applications.

Liang J, Deng X, Zhang Y, Fei T, Ouyang M, Yu C Front Genet. 2024; 15:1482929.

PMID: 39664728 PMC: 11633769. DOI: 10.3389/fgene.2024.1482929.


Transcription Factor Forkhead Box Protein 3 (FOXP3) as a Prognostic Indicator for Postoperative Outcomes in Patients with Breast Cancer: Establishment of a Prognostic Nomogram.

Tan C, Xu J, Zhang S, Liu S, Yang X, Wu D Breast Cancer (Dove Med Press). 2024; 16:705-723.

PMID: 39464238 PMC: 11505482. DOI: 10.2147/BCTT.S484055.


Stromal lymphocytes are associated with upgrade of B3 breast lesions.

Kader T, Provenzano E, Jayawardana M, Hendry S, Pang J, Elder K Breast Cancer Res. 2024; 26(1):115.

PMID: 38978071 PMC: 11232297. DOI: 10.1186/s13058-024-01857-y.


Benign breast tumors may arise on different immunological backgrounds.

Torland L, Lai X, Kumar S, Riis M, Geisler J, Luders T Mol Oncol. 2024; 18(10):2495-2509.

PMID: 38757377 PMC: 11459044. DOI: 10.1002/1878-0261.13655.


Benign Breast Disease and Breast Cancer Risk in the Percutaneous Biopsy Era.

Sherman M, Vierkant R, Winham S, Vachon C, Carter J, Pacheco-Spann L JAMA Surg. 2023; 159(2):193-201.

PMID: 38091020 PMC: 10719829. DOI: 10.1001/jamasurg.2023.6382.

References
1.
Grigoriadis A, Gazinska P, Pai T, Irhsad S, Wu Y, Millis R . Histological scoring of immune and stromal features in breast and axillary lymph nodes is prognostic for distant metastasis in lymph node-positive breast cancers. J Pathol Clin Res. 2018; 4(1):39-54. PMC: 5783956. DOI: 10.1002/cjp2.87. View

2.
Dieci M, Radosevic-Robin N, Fineberg S, Van den Eynden G, Ternes N, Penault-Llorca F . Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group.... Semin Cancer Biol. 2017; 52(Pt 2):16-25. DOI: 10.1016/j.semcancer.2017.10.003. View

3.
Wein L, Savas P, Luen S, Virassamy B, Salgado R, Loi S . Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions. Front Oncol. 2017; 7:156. PMC: 5540942. DOI: 10.3389/fonc.2017.00156. View

4.
Hendry S, Salgado R, Gevaert T, Russell P, John T, Thapa B . Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in.... Adv Anat Pathol. 2017; 24(5):235-251. PMC: 5564448. DOI: 10.1097/PAP.0000000000000162. View

5.
Kos Z, Roblin E, Kim R, Michiels S, Gallas B, Chen W . Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. NPJ Breast Cancer. 2020; 6:17. PMC: 7217863. DOI: 10.1038/s41523-020-0156-0. View